VCI Wealth Management LLC Purchases 34,235 Shares of Pfizer Inc. $PFE

Key Points

• VCI Wealth Management purchased 34,235 Pfizer shares in the third quarter, valued at approximately $976,000. Institutional investors collectively own 68.36% of Pfizer’s outstanding stock.
• Investor attention is focused on Pfizer’s obesity-drug pipeline and its upcoming third-quarter results, with analysts expecting $0.73 in EPS and $15.88 billion in revenue. The projected EPS would be below the year-earlier figure, underscoring ongoing earnings pressure.
• Analyst sentiment remains mixed, with Pfizer carrying a consensus “Hold” rating and an average price target of $28.65. The company also maintains an attractive dividend, recently declaring a $0.43-per-share quarterly payout, equivalent to a 5.6% yield.

VCI Wealth Management LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 34,235 shares of the biopharmaceutical company's stock, valued at approximately $976,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Retirement Wealth Solutions LLC boosted its holdings in Pfizer by 144.6% during the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 509 shares during the period. Keb Asset Management LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $26,000. Field & Main Bank purchased a new position in Pfizer in the 2nd quarter worth approximately $27,000. Bullseye Investment Management LLC bought a new stake in Pfizer in the second quarter valued at approximately $28,000. Finally, Timbuktu Capital Management LLC bought a new stake in Pfizer in the second quarter valued at approximately $29,000. 68.36% of the stock is owned by institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analysts are watching Pfizer’s obesity pipeline for evidence of a potential long-term growth opportunity. A successful update could help offset concerns about slower growth elsewhere in the business. Pfizer Q3 preview: Analysts look to obesity pipeline amid diverging growth expectations
• Positive Sentiment: Pfizer’s roughly 6% dividend yield continues to appeal to income-oriented investors. At that yield, generating $500 in monthly dividend income would require approximately $106,454 invested, assuming the payout remains unchanged. How To Earn $500 a Month From Pfizer Stock Ahead of Q3 Earnings
• Neutral Sentiment: Pfizer is scheduled to report third-quarter results before the market open on November 3. The consensus forecast calls for earnings per share of $0.73 and revenue of $15.88 billion, making guidance and any changes to full-year expectations especially important. Top Wall Street Forecasters Revamp Pfizer Expectations Ahead Of Q3 Earnings
• Neutral Sentiment: Wall Street views are mixed, while Goldman Sachs expects an essentially in-line quarter. The divided outlook increases the likelihood of a significant stock reaction if Pfizer’s results or pipeline commentary differ from expectations. Pfizer Q3 preview: Goldman sees in-line quarter, pipeline in focus
• Negative Sentiment: The expected $0.73 quarterly EPS would be below the year-earlier result, signaling continued earnings pressure even though projected revenue of $15.88 billion would represent a solid quarterly base. What to expect from Pfizer’s Q3 earnings

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. JPMorgan Chase & Co. lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, October 9th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, October 13th. Bank of America lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Finally, Cantor Fitzgerald increased their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Thursday, October 8th. Five analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $28.65.

Pfizer Stock Up 0.7%

NYSE PFE opened at $30.73 on Tuesday. Pfizer Inc. has a 1 year low of $23.62 and a 1 year high of $31.04. The stock has a market capitalization of $175.16 billion, a PE ratio of 40.44, a PEG ratio of 2.00 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The business's 50-day moving average is $28.60 and its 200 day moving average is $26.82.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company posted $0.78 EPS. Pfizer's quarterly revenue was up 2.6% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. Pfizer's payout ratio is 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.